Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
STAT+
Pharma
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

ASH winners and losers: Hemophilia therapies show promise, Syros stumbles

  • Adam Feuerstein

By Adam Feuerstein Dec. 11, 2017

Reprints
ASH 2017 story card
Hyacinth Empinado/STAT

ATLANTA — This weekend’s American Society of Hematology (ASH) annual meeting was bit like playing in a Brooklyn children’s soccer tournament: Everyone got a congratulatory trophy just for showing up.

Well … not everyone. To extend the tortured P.C. soccer metaphor, Syros Pharmaceuticals (SYRS) was ejected with a red card. Unsportsmanlike conduct.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Amazon Prime for your prescriptions, virtual care during pregnancy,…
Amazon Prime for your prescriptions, virtual care during pregnancy, & AI for mental health
The ‘cancer growing in cancer medicine’: pharma money paid…
The ‘cancer growing in cancer medicine’: pharma money paid to doctors
Long-term study shows most prostate cancer patients don’t need…
Long-term study shows most prostate cancer patients don’t need aggressive treatment
Teva quits brand lobby PhRMA, in line to lead…
Teva quits brand lobby PhRMA, in line to lead generic lobby AAM
Venture capital is investing little in new treatment for…
Venture capital is investing little in new treatment for addiction, report finds
Generics: a missing piece in China’s Covid-19 crisis response
Generics: a missing piece in China’s Covid-19 crisis response

Recommended Stories